CYP2B6
Gastrointestinal & Hepatic System · Phase I & Phase II Xenobiotic Detoxification
Why might CYP2B6 come up in a medication review?
CYP2B6 makes an enzyme that metabolizes certain medicines and other foreign compounds. Any prescribing implication depends on the specific drug and a clinically interpreted genetic result.
- Common Gene Name
- cytochrome P450 family 2 subfamily B member 6
- NCBI Gene ID
- 1555
- Chromosome
- 19
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (4 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Efavirenz | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Efavirenz | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Ospemifene (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Gynecology | View source |
| Prasugrel (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Cardiology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Gastrointestinal & Hepatic System